Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Monte Rosa Therapeutics, Inc.

NASDAQ: GLUE · Life Sciences · 3 alerts · CIK 1826457

Share price
$9.16Close, Nov 16
Market cap
$783M
Shares outstanding
85.45MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Monte Rosa Therapeutics, Inc. filings on SEC EDGAR ↗

7:39 AM ET 8-K
Clinical Trial Data

Monte Rosa Therapeutics Clinical Trial Data

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.

Earnings call
Oct 1, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.